{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'per the Investigator opinion (eg, follow-up HPV test is negative or cervical', 'abnormality has been effectively treated). An annual follow-up is', 'recommended.', 'Section 1.2.4, Schedule of', 'The possibility of sample collection via local labs was added.', 'Patient', 'events Part 4: Table for PK', 'convenience', 'sampling (Year 1)', 'Section 1.2.5, Schedule of', 'The possibility of sample collection via local labs was added.', 'Patient', 'events Part 5: Table for PK', 'convenience', 'sampling (Year 2)', 'Section 4, Introduction and', '\"The MS disease activity criteria include having at least 2 recorded MS', 'Clarification', 'rationale', 'attacks; at least 1 MS relapse in the last year during treatment with an', 'IFNB or GA after having been on that therapy for at least 6 months,\" is', 'appended by \"and is currently still taking the same therapy\".', '\"For patients <50 kg: 0.24 mg/kg/day\" is appended by \"(this equates to', '12 mg/day for a 50 kg patient).', '\"MRI assessments will be available to investigators to assess safety\" is', 'added.', 'Section 6.1, Description of the', '\"During this visit patients will be reminded to continue their prior DMT\" is', 'Clarification', 'study', 'appended by \"(limited to interferon or GA', 'only).', 'Section 6.3, Interim analysis', 'The two database locks are clarified as a partial, informal interim lock', 'Clarification', 'and the final lock.', 'Section 6.4.1 Scientific', '\"The members will remain blinded until completion of the study\" is', 'Clarification', 'advisory committee', 'removed.', 'Section 7.1, Inclusion criteria', '102. Signed informed consent/assent \" is replaced with \"Signed written', 'Clarification', 'informed consent/assent', '104. \"treatment with an IFNB or GA after having been on that therapy for', 'at least 6 months\" is appended with \"months, and is currently still taking', 'the same therapy.\"', 'Section 7.2.2 Exclusion', 'E08 \"Unwilling to agree to use a reliable and effective contraceptive', 'Local health', 'criteria related to', 'method as defined for', 'authority request', 'alemtuzumab and/or', 'contraception in the informed consent form (ICF) when receiving a', 'mandatory background', 'course of alemtuzumab', 'therapies', 'treatment and for 4 months following that course of treatment (fertile', 'patients only)', '(Appendix A)\" is replaced with:', 'E08 \"Unwilling to agree to use a highly effective contraceptive method as', 'defined (Appendix A) when receiving a', 'course of alemtuzumab treatment and for 4 months following that course', 'of treatment (fertile patients only).', 'Section 7.2.3, Exclusion', 'The following was added: \"Re-screening could be possible due to logistic', 'Clarification', 'criteria related to the current', 'reasons (eg, blood samples defective, lost, or other reason, non-medical)', 'knowledge of alemtuzumab', 'or the conditions resolved for eligibility.\"', 'and study methodology', 'E29 \"Infection with hepatitis B, C viruses (positive serology). Was', 'appended with \"but not due to hepatitis immunization).', 'Section 8.1.1, Administration', '\"For patients <50 kg: 0.24 mg/kg/day\" is appended with \"(this equates to', 'Clarification', '12 mg/day for a 50 kg patient).\"', 'Section 8.1.1.1, Method of', 'The time of infusion relative to dilution is clarified. It is allowed to extend', 'Clarification', 'preparation at the clinical site', 'the infusion time if clinically indicated. Additional requirements for', 'infusion and monitoring are referenced.', 'Section 8.2,', 'An equivalent medication to \"oral prednisone/prednisolone 1 mg/kg or 50', 'Clarification', 'Noninvestigational medicinal', 'mg one dose, whichever is lower\" is allowed.', 'products', 'Property of the Sanofi Group - strictly confidential', 'Page 152', 'VV-CLIN-02544065 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Section 8.3.1, Methods of', '\"The MRI assessments will be available to the investigators to assess', 'Clarification', 'blinding', 'safety\" is added.', 'Section 8.7 Responsibilities', '\"Should\" is replaced by \"must\" in \"Any quality issue noticed with the', 'Clarification', 'receipt or use of an IMP (deficiency in condition, appearance, pertaining', 'documentation, labeling, expiration date, etc) should be promptly notified', 'Section 8.7.2, Return and/or', '\"Authorization for destruction will be given by the sponsor\" is prepended', 'Clarification', 'destruction of treatments', 'by \"Written\".', 'Section 8.8, Concomitant', '\"Concomitant use of alternative medications (eg, herbal treatments,', 'Clarification', 'medication', 'botanicals, etc) is prepended with \"A concomitant medication is any', 'treatment received by the patient concomitantly to any IMP(s).', 'Concomitant treatments have been detailed for all phases of the study', 'and are not limited to the treatment received with the IMP (treatment', 'phase).\"', '\"Therapy with disease-modifying MS treatments that the patient is', 'currently being administered (ie interferons and GA) will be permitted', 'during the screening and prior DMT Treatment Phase. Prior DMT will be', 'discontinued 7 days before alemtuzumab first administration. Refer to', 'Section 6.1 for further details\" is replaced with \"Therapy with disease-', 'modifying MS treatments that the patient is currently being administered', '(ie, limited to interferons and GA only) will be permitted during the', 'screening and prior DMT Treatment Phase. If the investigator determines', 'that the patient needs to be treated with another DMT, the patient will be', 'discontinued from the study. Prior DMT will be discontinued 7 days', 'before alemtuzumab first administration. Refer to Section 6.1 for further', 'details.\"', '\"No concomitant therapy with any disease-modifying MS treatments', 'either licensed or investigational, including interferons and GA, will be', 'permitted during the alemtuzumab treatment\" is replaced appended with', '\"phase. If the investigator determines that the patient needs to be treated', 'with another DMT, the patient will be discontinued from the study.\"', 'Section 9.1.1.1, Brain MRI', '\"The MRI assessments will also be available to the investigators to', 'Clarification', 'assess safety\" is added.', 'Section 9.2, Secondary', 'A summary of secondary endpoints is added.', 'Clarification', 'endpoints', 'Section 9.2.1.3.1, Brief', '\"Central scoring will be performed by an independent rater who is blinded', 'Clarification', 'visuospatial memory test -', 'to treatments (ie, current DMT or alemtuzumab)\" is added.', 'revised', '9.2.1.3.2 ,Symbol digit', 'It is clarified that oral responses are expected of the patient, which will be', 'Clarification', 'modality test', 'written down by the person administering the test.', 'Section 9.3.2, Laboratory', 'Text regarding HPV testing is added.', 'Request of local', 'safety variables', 'health authorities', 'Section 10.1.1, Visit 1', 'Race is added to the demographic variables collected. HPV testing is', 'Clarification', 'Screening visit:', 'added to the list of serology tests performed. \"The MRI assessments will', 'be available to investigators to assess safety\" is added.', 'Section 10.1.3, Visit 3/Day-7:', 'The section title is changed to Visit 3/Day -14 to -7. Urine sampling is', 'Clarification', 'added.', 'Section 10.1.10, Visit 16/M12', 'Urine sampling is added', 'Clarification', '(second course of', 'alemtuzumab):', 'Property of the Sanofi Group - strictly confidential', 'Page 153', 'VV-CLIN-0254406 5.0']\n\n###\n\n", "completion": "END"}